Genetic profile for suspected dysferlinopathy identified by targeted next-generation sequencing
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective: To investigate the genetic causes of suspected dysferlinopathy and to reveal the genetic profile for myopathies with dysferlin deficiency.
Methods: Using next-generation sequencing, we analyzed 42 myopathy-associated genes, including DYSF, in 64 patients who were clinically or pathologically suspected of having dysferlinopathy. Putative pathogenic mutations were confirmed by Sanger sequencing. In addition, copy-number variations in DYSF were investigated using multiplex ligation-dependent probe amplification. We also analyzed the genetic profile for 90 patients with myopathy with dysferlin deficiency, as indicated by muscle specimen immunohistochemistry, including patients from a previous cohort.
Results: We identified putative pathogenic mutations in 38 patients (59% of all investigated patients). Twenty-three patients had DYSF mutations, including 6 novel mutations. The remaining 16 patients, including a single patient who also carried the DYSF mutation, harbored putative pathogenic mutations in other genes. The genetic profile for 90 patients with dysferlin deficiency revealed that 70% had DYSF mutations (n = 63), 10% had CAPN3 mutations (n = 9), 2% had CAV3 mutations (n = 2), 3% had mutations in other genes (in single patients), and 16% did not have any identified mutations (n = 14).
Conclusions: This study clarified the heterogeneous genetic profile for myopathies with dysferlin deficiency. Our results demonstrate the importance of a comprehensive analysis of related genes in improving the genetic diagnosis of dysferlinopathy as one of the most common subtypes of limb-girdle muscular dystrophy. Unresolved diagnoses should be investigated using whole-genome or whole-exome sequencing.
GLOSSARY
- CK=
- creatine kinase;
- DM=
- distal myopathy;
- HGMD=
- Human Gene Mutation Database;
- LGMD=
- limb-girdle muscular dystrophy;
- MLPA=
- multiplex ligation-dependent probe amplification;
- MMD=
- Miyoshi muscular dystrophy;
- XHMM=
- eXome-Hidden Markov Model
Footnotes
Funding information and disclosures are provided at the end of the article. Go to Neurology.org/ng for full disclosure forms. The Article Processing Charge was paid by the authors.
Supplemental data at Neurology.org/ng
- Received August 24, 2015.
- Accepted in final form October 26, 2015.
- © 2015 American Academy of Neurology
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Articles
Frequency of LGMD gene mutations in Italian patients with distinct clinical phenotypesM. Fanin, A. C. Nascimbeni, S. Aurino et al.Neurology, April 20, 2009 -
Articles
Symptomatic dysferlin gene mutation carriers: Characterization of two casesI. Illa, N. De Luna, R. Domínguez-Perles et al.Neurology, February 07, 2007 -
Articles
Calpain-3 and dysferlin protein screening in patients with limb–girdle dystrophy and myopathyM. Fanin, E. Pegoraro, C. Matsuda–Asada et al.Neurology, March 13, 2001 -
Resident and Fellow Section
Clinical Reasoning: A 30-year-old man with progressive weakness and atrophyColin Quinn, Steven A. Moore, Tanya M. Bardakjian et al.Neurology, November 07, 2016